The present invention relates to a pharmaceutical composition comprising one or more endocannabinoids, cannabinoids and/or modified versions thereof complexed with one or more lipoproteins, wherein said one or more endocannabinoids are selected from N-acylethanolamides, N-acyl dopamines, 2-acyl glycerols and 2-glyceryl ethers and wherein said one or more cannabinoids are selected from cannabinols, cannabidiols and tetrahydrocannabinols. Further, the invention relates to the use of said pharmaceutical composition in the treatment of a tumour in a mammal. Also, the invention relates to a method for modulating the activity of the hedgehog signaling pathway in a mammalian cell and the use of one or more endocannabinoids, cannabinoids and modified versions thereof in the differentiation of embryonic stem cells, progenitor cells and/or induced stem cells.
